에서 실시간으로 운영 중이에요! 자세히 알아보기

ImmunityBio

IBRX

시가총액 US$97.3억

9.18 USD

-0.82

8.2%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

9.17

-0.01

0.11%

1일

-8.2%

5일

-13.31%

1개월

16.06%

3개월

23.22%

6개월

26.62%

연초 이후

354.46%

1년

262.85%

5년

2.8%

10년

47.35%

소개: ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

직원 수: 691

건강관리 생명공학

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 50%

중립 50%

부정적 0%

ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study (N=100) in the Journal of Urology. The study evaluated ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease. Highl.

ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors

Zacks Investment Research

FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer

IBRX wins expanded FDA approval for Anktiva plus BCG, covering all patients with BCG-unresponsive NMIBC and broadening its commercial opportunity.

FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer

ImmunityBio Stock Climbs Thursday: What's Going On?

ImmunityBio Inc. (NASDAQ:IBRX) shares are trading higher Thursday after the FDA expanded the approved indication for its bladder cancer immunotherapy ANKTIVA to include BCG-unresponsive non-muscle-invasive bladder cancer with papillary-only tumors.

ImmunityBio Stock Climbs Thursday: What's Going On?

FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) to include patients with BCG-unresponsive NMIBC with papillary-only tumors. The expanded FDA label reads as follows: ANKTIVA, in combination with Bacillus Calmette-Guérin (BCG), is in.

FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Chairman and Global Chief Scientific and Medical Officer, will participate virtually in a fireside chat at the Piper Sandler Virtual Oncology Symposium, taking place October 15-16, 2026. Details of the event are provided below: Piper Sandler Virtual Oncology Symposium – Fireside Chat Participant: Patrick Soon-Shion.

ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium

ImmunityBio Stock Jumps: What's Going On?

ImmunityBio Inc. (NASDAQ:IBRX) shares are soaring Friday, extending a steadily rising pattern that's played out over the past several months.

ImmunityBio Stock Jumps: What's Going On?

Zacks Investment Research

ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?

ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?

Undercovered Dozen: Blue Owl Capital, Archer Aviation, Apollo Commercial And More

The Undercovered Dozen series spotlights 12 lesser-covered stocks featured on Seeking Alpha. This curated selection aims to provide fresh investment ideas and foster community discussion around under-the-radar equities. Readers are encouraged to engage, share perspectives, and highlight additional overlooked investment opportunities.

Undercovered Dozen: Blue Owl Capital, Archer Aviation, Apollo Commercial And More

Zacks Investment Research

Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?

ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock?

Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?

ImmunityBio: None Of The Moonshots Is Priced In

ImmunityBio is rated a strong buy, driven by ANKTIVA's FDA approval for BCG-unresponsive NMIBC and significant pipeline expansion potential. Current valuation reflects success in bladder cancer and BCG-naïve expansion, but assigns limited value to systemic immunotherapy potential in NSCLC or other types of cancer. Key near-term catalysts include phase 3 NSCLC data and BCG-naïve bladder cancer trial results, both of which could unlock substantial upside.

ImmunityBio: None Of The Moonshots Is Priced In

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.